Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,198

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,198 results for “Vaccination and immunization”

Learn how ShareScore rates datasets ↗
zenodo32/100

Safety and immunogenicity of heterologous booster immunization with Ad5-nCoV after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults: a randomized, double-blind, parallel-controlled trial

<p>Data on safety and immunity of heterologous booster (fourth dose) after three-dose priming with inactivated SARS-CoV-2 vaccine are limited in Chinese adults. Here, we evaluate the safety and immunogenicity of immunization with Ad5-nCoV in a randomized, double-blind, parallel-controlled phase 4 clinical trial in Zhejiang, China (NCT05373030). Participants aged 18-80 years (100 participants per group) who have administered three doses of inactivated SARS-CoV-2 vaccine &ge; 6-month earlier were enrolled and randomized at 1:1 into two groups, then administered intramuscular Ad5-nCoV or different inactivated SARS-CoV-2 vaccine (CoronaVac or Covilo) respectively. All observed adverse reactions were predictable and manageable. Ad5-nCoV elicited significantly higher RBD-specific IgG levels, with a GMC of 2924.0 on day 14 post-booster, 7.8-fold that of the inactivated vaccine. Pseudovirus-neutralizing antibodies to Omicron BA.4/5 showed a similar pattern, with GMT of 228.9 in the Ad5-nCoV group and 65.5 in the inactivated vaccine group. The Ad5-nCoV booster-maintained a high antibody levels on day 90, with seroconversion of 71.4%, while the inactivated vaccine group was 5.2%, closed to pre-booster levels. In summary, a fourth Ad5-nCoV vaccination following three-dose inactivated SARS-CoV-2 vaccination is immunogenic, tolerable, and more efficient than inactivated SARS-CoV-2 vaccine. Ad5-nCoV elicits a stronger humoral response against Omicron BA.4/5 and maintains antibody levels for longer than homologous boosting.</p>

opencc-by-4.0May 2023View details →
ClinicalTrials.gov32/100

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

ClinicalTrials.gov study NCT01194180. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy

ClinicalTrials.gov study NCT06333275. IPD Sharing: UNDECIDED. Countries: 1. Publications: 11.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

ClinicalTrials.gov study NCT00376090. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

ClinicalTrials.gov study NCT00119873. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

ClinicalTrials.gov study NCT00488046. IPD Sharing: Not stated. Countries: 1. Publications: 6.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

ClinicalTrials.gov study NCT00486408. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria

ClinicalTrials.gov study NCT00870987. IPD Sharing: Not stated. Countries: 1. Publications: 6.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

ClinicalTrials.gov study NCT00189917. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

ClinicalTrials.gov study NCT02040831. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

ClinicalTrials.gov study NCT04858568. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Giving Immunizations Through Vaccine Education

ClinicalTrials.gov study NCT01159093. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure

ClinicalTrials.gov study NCT06681636. IPD Sharing: NO. Countries: 2. Publications: 9.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

ClinicalTrials.gov study NCT01260727. IPD Sharing: Not stated. Countries: 4. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

ClinicalTrials.gov study NCT01436422. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®

ClinicalTrials.gov study NCT01054053. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

ClinicalTrials.gov study NCT00308412. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

ClinicalTrials.gov study NCT02296983. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI

ClinicalTrials.gov study NCT05043272. IPD Sharing: NO. Countries: 1. Publications: 9.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults

ClinicalTrials.gov study NCT01103687. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record